Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer



Status:Active, not recruiting
Conditions:Ovarian Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/4/2018
Start Date:December 27, 2010

Use our guide to learn which trials are right for you!

A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This randomized phase II trial studies how well bevacizumab with or without everolimus works
in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube
cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block
tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
Others find tumor cells and help kill them or carry tumor-killing substances to them.
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Bevacizumab and everolimus may also stop the growth of tumor cells by blocking blood
flow to the tumor. It is not yet known whether bevacizumab is more effective when given
together with or without everolimus in treating ovarian epithelial cancer, fallopian tube
cancer, or primary peritoneal cancer.

PRIMARY OBJECTIVES:

I. To estimate the progression-free survival hazard ratio of the combination of oral
everolimus (RAD001) and bevacizumab compared to oral placebo and bevacizumab in patients with
persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

SECONDARY OBJECTIVES:

I. To determine the nature and degree of toxicity of oral everolimus (or placebo) plus
bevacizumab.

II. To characterize and compare progression-free survival and overall survival in patients
with measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] criteria) and
patients with detectable (non-measurable) disease.

III. To estimate the proportion of patients with measurable disease who have objective tumor
responses by treatment.

IV. To provide descriptive information about cancer antigen (CA)-125 responses by regimen and
where possible by objective tumor responses.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15
and everolimus orally (PO) once daily (QD) on days 1-28.

ARM II: Patients receive bevacizumab as in Arm I and placebo PO QD on days 1-28.

In both arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 2 years and
then every 6 months for 3 years.

Inclusion Criteria:

- Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or
primary peritoneal carcinoma; histologic documentation of the original primary tumor
is required via the pathology report

- Patients must have measurable disease or detectable (non-measurable) disease:

- Measurable disease is defined as at least one lesion that can be accurately
measured in at least one dimension (longest dimension to be recorded); each
lesion must be greater than or equal to 10 mm when measured by computed
tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by
clinical exam; or greater than or equal to 20 mm when measured by chest x-ray;
lymph nodes must be greater than or equal to 15 mm in short axis when measured by
CT or MRI

- Detectable disease in a patient is defined as one who does not have measurable
disease but has at least one of the following conditions:

- Baseline values of CA-125 at least 2 x upper limit of normal (ULN)

- Ascites and/or pleural effusion attributed to tumor

- Solid and/or cystic abnormalities on radiographic imaging that do not meet
RECIST 1.1 definitions for target lesions

- Patients in the measurable disease cohort must have at least one ?target lesion? to be
used to assess response on this protocol as defined by RECIST 1.1; tumors within a
previously irradiated field will be designated as ?non-target? lesions unless
progression is documented or a biopsy is obtained to confirm persistence at least 90
days following completion of radiation therapy

- Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG)
protocol, if one exists; in general, this would refer to any active GOG phase III
protocol or Rare Tumor Protocol for the same patient population

- Patients who have had one prior treatment must have a GOG performance status of 0, 1,
or 2; patients who have had two or three prior treatments must have a GOG performance
status of 0 or 1

- Patients should be free of active infection requiring parenteral antibiotics (with the
exception of uncomplicated urinary tract infection [UTI])

- Recovery from effects of recent surgery, radiotherapy, or chemotherapy

- Any hormonal therapy directed at the malignant tumor must be discontinued at
least one week prior to registration

- Any other prior therapy directed at the malignant tumor, including biological and
immunologic agents, must be discontinued at least 3 weeks prior to registration
(including small molecules and murine monoclonal antibodies); chimeric or human
or humanized monoclonal antibodies (including bevacizumab) or vascular
endothelial growth factor (VEGF) receptor fusion protein (including VEGF Trap,
aflibercept) must be discontinued for at least 12 weeks prior to registration; no
investigational therapy within 30 days prior to the first date of study treatment

- Prior therapy:

- Patients must have had one prior platinum-based chemotherapeutic regimen for
management of primary disease containing carboplatin, cisplatin, or another
organoplatinum compound' this initial treatment may have included intraperitoneal
therapy, consolidation, non-cytotoxic agents or extended therapy administered
after surgical or non-surgical assessment

- Patients are allowed to receive, but are not required to receive, two additional
cytotoxic regimens for management of recurrent or persistent disease, with no
more than 1 non-platinum, non-taxane regimen

- Patients are allowed to receive, but are not required to receive, biologic
(non-cytotoxic) therapy as part of their primary treatment regimen; patients must
have NOT received any non-cytotoxic therapy for management of recurrent or
persistent disease

- Patients who have received only one prior cytotoxic regimen (platinum-based
regimen for management of primary disease), must have a platinum-free interval of
less than 12 months, or have progressed during platinum-based therapy, or have
persistent disease after a platinum-based therapy

- For the purposes of this study, poly (adenosine diphosphate [ADP]-ribose)
polymerase (PARP) inhibitors will be considered ?cytotoxic,? and prior treatment
with PARP inhibitors for primary or recurrent disease WILL be allowed (either
alone or in combination with chemotherapy)

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl

- Platelets greater than or equal to 100,000/mcl

- Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN)

- Bilirubin less than or equal to 1.5 x ULN

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) less
than or equal to 3 x ULN

- Alkaline phosphatase less than or equal to 2.5 x ULN

- Prothrombin time (PT) such that international normalized ratio (INR) is less than or
equal to 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a
stable dose of therapeutic warfarin for management of deep vein thrombosis including
pulmonary embolism)

- Partial thromboplastin time (PTT) less than or equal to 1.5 times the upper limit of
normal

- Fasting serum cholesterol less than or equal to 300 mg/dL OR less than or equal to
7.75 mmol/L AND

- Fasting triglycerides less than or equal to 300 mg/dL or 3.42 mmol/L

- Urine protein creatinine (UPC) ratio must be < 1.0 gm; if UPC ratio >= 1, collection
of 24-hour urine measurement of urine protein is recommended; UPC ratio of spot urine
is an estimation of the 24-hour urine protein excretion?a UPC ratio of 1 is roughly
equivalent to a 24-hour urine protein of 1 gm

- Patients of childbearing potential must have a negative serum pregnancy test prior to
the study entry and be practicing an effective form of contraception

- Patients must have signed an approved informed consent and authorization permitting
the release of personal health information

- Patients must meet pre-entry requirements

- Patients with clinically significant cardiovascular disease; this includes:

- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm
Hg

- Myocardial infarction or unstable angina within 6 months prior to registration

- New York Heart Association (NYHA) class II or greater congestive heart failure

- Serious cardiac arrhythmia requiring medication; this does not include
asymptomatic, atrial fibrillation with controlled ventricular rate

- Patients who have received prior treatment with an anthracycline (including
doxorubicin and or liposomal doxorubicin) and have an ejection fraction < 50%

- Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greater
peripheral vascular disease (at least brief [< 24 hours (hrs)] episodes of
ischemia managed non-surgically and without permanent deficit)

Exclusion Criteria:

- Patients who have received prior everolimus or any other mammalian target of rapamycin
(mTOR) inhibitor

- Patients with other invasive malignancies, with the exception of non-melanoma skin
cancer and other specific malignancies, are excluded if there is any evidence of other
malignancy being present within the last three years; patients are also excluded if
their previous cancer treatment contraindicates this protocol therapy

- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis OTHER THAN for the treatment of ovarian, fallopian tube or primary
peritoneal cancer within the last three years are excluded; prior radiation for
localized cancer of the breast, head and neck, or skin is permitted, provided that it
was completed more than three years prior to registration, and the patient remains
free of recurrent or metastatic disease

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER
THAN for the treatment of ovarian, fallopian tube or primary peritoneal cancer within
the last three years are excluded; patients may have received prior adjuvant
chemotherapy for localized breast cancer, provided that it was completed more than
three years prior to registration, and the patient remains free of recurrent or
metastatic disease

- Patients with serious non-healing wound, ulcer, or bone fracture; this includes
history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 28 days prior to the first date of study treatment

- Patients with active bleeding or pathologic conditions that carry high risk of
bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major
vessels

- Patients with history or evidence upon physical examination of central nervous system
(CNS) disease, including primary brain tumor, seizures not controlled with standard
medical therapy, any brain metastases, or history of cerebrovascular accident (CVA,
stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months
prior to the first date of study treatment

- Known hypersensitivity to murine or chimeric antibodies

- Major surgery within 28 days prior to the first date of study treatment

- Patients with clinical symptoms or signs of gastrointestinal obstruction and patients
who require parenteral hydration and/or nutrition

- Patients with medical history or conditions not otherwise previously specified which
in the opinion of the investigator should exclude participation in this study; the
investigator can consult the Study Chair or Study Co-Chairs for uncertainty in this
regard

- Patients who are pregnant or nursing

- Patients with active hepatitis B or C

- Laboratory confirmation to exclude hepatitis B and C is required in any patient
considered at high risk for hepatitis B or C; risk factors can include:

- You currently live in (or have lived in) Asia, Africa, Central and South
America, Eastern Europe, Spain, Portugal, and Greece

- Known or suspected past hepatitis B infection

- Known or suspected past hepatitis C infection (including past interferon
?curative? treatment)

- Blood transfusion(s) prior to 1990

- Current or prior IV drug use

- Current or prior dialysis

- Household contact with hepatitis B or hepatitis C infected person(s)

- Current or prior high-risk sexual activity

- Body piercing or tattoos

- Mother known to have hepatitis B

- History suggestive of hepatitis B infection, e.g., dark urine, jaundice,
right upper quadrant pain
We found this trial at
45
sites
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
1111 Duff Ave
Ames, Iowa 50010
(866) 972-5477
McFarland Clinic PC-William R Bliss Cancer Center The William R. Bliss Cancer Center at Mary...
?
mi
from
Ames, IA
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Burbank, CA
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
Charlotte, North Carolina 28204
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
(216) 778-7800
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
(515) 241-6212
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
(515) 247-3121
Mercy Medical Center - Des Moines Mercy Medical Center
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
700 E University Ave
Des Moines, Iowa 50316
(515) 263-5612
Iowa Lutheran Hospital Iowa Lutheran Hospital has a long history of serving the Des Moines...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Hinsdale, IL
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46260
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Mayfield Heights, Ohio 44124
?
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
9485 Mentor Ave
Mentor, Ohio 44060
(440) 205-5755
Lake University Ireland Cancer Center Lake Health is a private, not-for-profit leader in community health...
?
mi
from
Mentor, OH
Click here to add this to my saved trials
100 Grand St
New Britain, Connecticut 06050
(860) 224-5011
The Hospital of Central Connecticut The Hospital of Central Connecticut is dedicated to fostering, sustaining...
?
mi
from
New Britain, CT
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85012
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Providence, Rhode Island 02905
?
mi
from
Providence, RI
Click here to add this to my saved trials
8th Ave & C St
Salt Lake City, Utah 84143
(801) 408-1100
LDS Hospital LDS Hospital provides clinical excellence to our community in a wide range of...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
759 Chestnut Street
Springfield, Massachusetts 01199
(413) 794 - 0000
Baystate Medical Center Baystate Medical Center (BMC), in Springfield, Massachusetts, is an academic, research, and...
?
mi
from
Springfield, MA
Click here to add this to my saved trials
1235 E Cherokee St
Springfield, Missouri 65804
(417) 820-2000
Mercy Hospital Springfield We're continuing a tradition of healing more than 120 years old. Mercy...
?
mi
from
Springfield, MO
Click here to add this to my saved trials
3801 South National Avenue
Springfield, Missouri 65807
(417) 269-6000
CoxHealth South Hospital U.S. News & World Report has ranked CoxHealth one of Missouri's best...
?
mi
from
Springfield, MO
Click here to add this to my saved trials
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
602 W University Ave
Urbana, Illinois 61801
(217) 383-3010
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
300 South 6th Avenue
West Reading, Pennsylvania 19611
(610) 988-8000
Reading Hospital At Reading Health System, advancing your health and wellness is our mission. When...
?
mi
from
West Reading, PA
Click here to add this to my saved trials